Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Jul 18:16:1624943.
doi: 10.3389/fimmu.2025.1624943. eCollection 2025.

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer

Xuchen Zhang  1 , Yulong Tian  2 , Huiyun Wang  1 , Shanai Song  1 , Yunqing Chen  3 , Ning Liu  1 , Chuantao Zhang  1 , Xiao Huang  1 , Haitao Jiang #  2 , Helei Hou #  1
Affiliations
Observational Study

Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy for patients with potentially resectable stage III to IVB HER2-positive gastric cancer

Xuchen Zhang et al. Front Immunol. .

Abstract

Background: Whether the addition of trastuzumab to chemo(immuno)therapy for the preoperative treatment of patients with potentially resectable HER2-positive gastric cancer has clinical benefits remains to be explored. This real-world observational study was designed to evaluate the efficacy and safety of trastuzumab plus chemo(immuno)therapy for neoadjuvant or conversion therapy in patients with potentially resectable HER2-positive gastric cancer.

Methods: We retrospectively collected the clinical data of treatment-naïve patients with potentially resectable stage III to IVB HER2-positive gastric cancer who received preoperative therapy prior to D2 gastrectomy. The main outcomes of interest included tumour regression grade (TRG), treatment-related adverse events (TRAEs), and event-free survival (EFS).

Results: A total of 40 patients were included in the analysis, specifically, 27 patients (67.5%, 95% CI 0.520-0.799) received preoperative trastuzumab plus chemo(immuno)therapy, and 13 patients (32.5%, 95% CI 0.201-0.480) received chemo(immuno)therapy. All these patients subsequently underwent D2 gastrectomy. Regarding surgical outcomes, TRG0/1 rates were 33.3% (95% CI 0.186-0.522) in the trastuzumab-containing treatment group and 15.4% (95% CI 0.043-0.422) in the chemotherapy/chemoimmunotherapy group. Regarding safety, 66.7% (95% CI 0.478-0.814) of patients in the trastuzumab-containing treatment group and 61.5% (95% CI 0.355-0.823) of patients in the chemotherapy/chemoimmunotherapy group experienced preoperative TRAEs. The probabilities of EFS were not statistically significant between the two groups by the last follow-up.

Conclusion: Additions of trastuzumab to preoperative chemotherapy or chemoimmunotherapy resulted in a TRG0/1 rate of 33.3% among patients with potentially resectable HER2-positive gastric cancer, and the combined regimen exhibited a favourable safety profile.

Keywords: HER2-positive gastric cancer; immune checkpoint blockade; preoperative therapy; trastuzumab; tumour regression grade.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Assessments of best tumour responses to preoperative treatment based on RECIST and surgical outcomes of the patients.
Figure 2
Figure 2
Tumour response in a patient who received preoperative treatment with trastuzumab, pembrolizumab, and XELOX chemotherapy, and subsequently achieved a pathological TRG0. (A) H&E staining images (a) at baseline and (b–e) post-operative. (B) Radiographical images at baseline and after preoperative treatment. (C) Gastroscopy images at 32 months post-surgery, with no evidence of recurrence observed.
Figure 3
Figure 3
Treatment process and Kaplan–Meier curves for event-free survival (EFS). (A) Swimmer plot of the treatment process and follow-up of the patients from the time of diagnosis. (B–D) Kaplan–Meier curves for EFS (B) in patients receiving trastuzumab-containing treatment versus patients receiving chemo(immuno)therapy (P=0.487), (C) in patients receiving trastuzumab plus chemotherapy versus patients receiving chemotherapy alone (P=0.364), and (D) in patients receiving trastuzumab, PD-1 blockade and chemotherapy versus patients receiving PD-1 blockade plus chemotherapy (P=0.988).
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2024) 74:229–63. doi: 10.3322/caac.21834, PMID: - DOI - PubMed
    1. Boku N. HER2-positive gastric cancer. Gastric Cancer. (2014) 17:1–12. doi: 10.1007/s10120-013-0252-z, PMID: - DOI - PMC - PubMed
    1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. (2006) 355:11–20. doi: 10.1056/NEJMoa055531, PMID: - DOI - PubMed
    1. Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. (2023) 25:212–24. doi: 10.1016/S1470-2045(23)00541-7, PMID: - DOI - PubMed
    1. Janjigian YY, Al-Batran S-E, Wainberg ZA, Cutsem EV, Molena D, Muro K, et al. Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. J Clin Oncol. (2024) 42:LBA246–6. doi: 10.1200/JCO.2024.42.3_suppl.LBA246 - DOI

Publication types

MeSH terms